Increased IL-1beta production from dsRNA-stimulated leukocytes in febrile seizures.
This study examined the possibility that children with and without a history of febrile seizures might mount different immune responses to double-stranded ribonucleic acid, which is a common viral factor that induces host cell immune responses, and is recognized by Toll-like receptor 3. The production of interleukin-1beta and interferon-alpha from double-stranded ribonucleic acid-stimulated leukocytes was examined in 27 children (age 3.6+/-0.3 years) with a history of febrile seizures and in 18 children (age 3.4+/-0.2 years) without a history of febrile seizures. Significantly (P=0.0007) increased interleukin-1beta production was observed in children with a history of febrile seizures, compared with control subjects. When patients with a single prior episode of febrile seizures (n=9) and those with multiple prior episodes of febrile seizures (n=18) were compared, a significant difference in interleukin-1beta production was not observed. Genotyping of interleukin-1beta(-511), Toll-like receptor 3, Toll-IL-1 receptor domain-containing adapter inducing interferon-beta, and interleukin-1 receptor antagonist polymorphisms revealed no significant differences in allelic distribution among febrile seizure patients and control subjects. Interleukin-1beta production was not significantly influenced by genotype. Viral infection results in increased interleukin-1beta production in febrile seizure patients, and this may play a role in febrile seizures.
Matsuo
Muneaki
M
Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan. matsuo@cc.saga-u.ac.jp
Sasaki
Kazuya
K
Ichimaru
Tomohiro
T
Nakazato
Sachie
S
Hamasaki
Yuhei
Y
D033942:Adaptor Proteins, Vesicular Transport / Q000235:genetics; D016022:Case-Control Studies; D018929:Cell Culture Techniques; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D016898:Interferon-alpha / Q000378:metabolism; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000378:metabolism*; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics; D012330:RNA, Double-Stranded / Q000494:pharmacology*; D003294:Seizures, Febrile / Q000235:genetics* / Q000276:immunology* / Q000473:pathology; D012795:Sialoglycoproteins / Q000235:genetics; D051196:Toll-Like Receptor 3 / Q000235:genetics
D033942:Adaptor Proteins, Vesicular Transport; C507763:IL1RN protein, human; D016898:Interferon-alpha; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D012330:RNA, Double-Stranded; D012795:Sialoglycoproteins; C470409:TICAM1 protein, human; C495344:TLR3 protein, human; D051196:Toll-Like Receptor 3